NLM Digital Collections

Search

Start Over Subjects Drugs, Generic -- economics ✖Remove constraint Subjects: Drugs, Generic -- economics

1. Snapshots of recent state initiatives in Medicaid prescription drug cost control

Author(s):
Young, Katherine, author
Garfield, Rachel, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Cost Control -- statistics & numerical data
Cost Control -- trends
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicaid -- trends
Disclosure
Drugs, Generic -- economics
Economics, Pharmaceutical
Federal Government
Forecasting
Formularies as Topic
State Government
Humans
United States
United States. Food and Drug Administration.

2. Trends in P2Y12 receptor inhibitor use and adherence after percutaneous coronary intervention, 2008-2016

Author(s):
Dayoub, Elias J., author
Seigerman, Matthew, author
Tuteja, Sony, author
Kobayashi, Taisei, author
Kolansky, Daniel, author
Giri, Jay, author
Groeneveld, Peter, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Medication Adherence -- statistics & numerical data
Percutaneous Coronary Intervention
Purinergic P2Y Receptor Antagonists -- therapeutic use
Socioeconomic Factors
Drug Costs
Drugs, Generic -- economics
Drugs, Generic -- therapeutic use
Platelet Aggregation Inhibitors -- economics
Platelet Aggregation Inhibitors -- therapeutic use
Purinergic P2Y Receptor Antagonists -- economics
Social Determinants of Health
Humans
United States

3. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

5. Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:
Washington, D.C. : U.S. Government Accountability Office, May 2017
Subject(s):
Drugs, Generic -- economics
Drugs, Investigational -- economics
Investigational New Drug Application -- economics
Drug Approval -- economics
Humans
United States
United States. Food and Drug Administration.

10. Rx Watchdog report: comparative measures of price change for prescription drugs and other goods

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Drug Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- trends
Drugs, Generic -- economics
Forecasting
Health Expenditures -- trends
Inflation, Economic
Humans
United States

12. Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:
Washington, D.C. : AARP Public Policy Institute, c2012
Subject(s):
Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- statistics & numerical data
Drugs, Generic -- economics
Forecasting
Pharmaceutical Preparations -- economics
Humans
United States

14. Generic drugs: Stakeholder views on improving FDA’s information on patents : report to congressional committees

Publication:
Washington, DC : United States Government Accountability Office, March 2023
Subject(s):
Drugs, Generic -- economics
Drug Development -- legislation & jurisprudence
Government Regulation
Legislation, Medical
Patents as Topic -- legislation & jurisprudence
Prescription Fees -- legislation & jurisprudence
United States

16. A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Author(s):
Purvis, Leigh, author
Publication:
Washington, D.C. : AARP Public Policy Institute, September 2014
Subject(s):
Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
Drugs, Generic -- economics
Federal Government
State Government
Humans
United States
United States. Food and Drug Administration.
United States.

22. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

23. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

25. Utilization and spending trends in Medicaid outpatient prescription drugs

Author(s):
Young, Katherine, author
Publication:
[San Francisco, California] : Henry J. Kaiser Family Foundation, February 2019
Subject(s):
Drug Utilization -- economics
Drug Utilization -- trends
Health Expenditures -- trends
Medicaid -- economics
Medicaid -- trends
Prescription Drugs -- economics
Drugs, Generic -- economics
Forecasting
Humans
United States

Refine by: